Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 146Small Cell Lung Carcinoma 146Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 86Head and Neck Neoplasms 80Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Esophageal Neoplasms 72Adenocarcinoma of Lung 71Neuroblastoma 55Central Nervous System Neoplasms 53Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

Etoposide 4Carboplatin 4atezolizumab 3pembrolizumab 2Radiotherapy 2tislelizumab 1sintilimab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Epirubicin 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Small Cell Lung Cancer Extensive Stage × Carboplatin × Clear all
NCT07227597 2026-05-28

MK-6070-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
170 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT05856695 2025-09-24

TAXIO

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Active not recruiting
67 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06739928 2024-12-18

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Guangzhou Institute of Respiratory Disease

Phase 2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡